HLHui Li

Hui Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Li has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Hui

    State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of -Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China

    6 shared publications
  • Jingyan Xu

    Department of Hematology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China

    3 shared publications
  • Po Hu

    School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Qixia District, Nanjing 210023, China

    3 shared publications
  • Qinglong Guo

    School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University Nanjing Jiangsu China

    3 shared publications
  • Hongzheng Wang

    School of Pharmacy/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Shihezi University, Shihezi, P. R. China

    2 shared publications
  • Hong‐Yu Chen

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University Nanjing People's Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Chidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin

    by Yun‐Yan Yin, Yu Liu, Yi‐Qi Lu, Zhi‐Meng Tang, Zheng‐Xin Zhu, Meng‐Yuan Zhu, Hong‐Yu Chen, Hui Hui, Jing‐Yan Xu, Hui Li

    Diffuse large B‐cell lymphoma (DLBCL), a heterogeneous malignancy characterized by distinct genetic and clinical subtypes, remains a therapeutic challenge despite standard R‐CHOP chemotherapy. This study systematically investigated the synergistic anti‐tumor efficacy and mechanism of the histone deacetylase inhibitor chidamide (CHI) combined with doxorubicin (DOX) in DLBCL models. Through multimodal experimental approaches including CCK8 proliferation assays, senescence‐associated β‐galactosidase (SA‐β‐gal) staining analysis, comet assay for DNA damage quantification, and comprehensive western blotting for molecular mechanism elucidation, we identified a potent synergistic interaction between CHI and DOX. By constructing a xenograft tumor model, the synergistic effect of the two drugs and its mechanism in vivo were confirmed. Our research found that CHI showed cell cycle inhibition and apoptosis induction effects on DLBCL cells. When combined with DOX, both synergistically inhibited the proliferation of DLBCL cells and promoted death of DOX‐induced senescent cells. Preliminary mechanism studies revealed that CHI can reduce the level of mutant p53, inhibit cell senescence, and induce irreparable DNA damage in DOX‐induced senescent tumor cells, ultimately leading them into programmed apoptosis. Thus, the “One‐two punch” strategy increased the sensitivity of p53‐mutated DLBCL cells to CHI. In summary, our study demonstrates that CHI synergizes with DOX to suppress DLBCL and presents a promising strategy to augment the therapeutic efficacy of DOX.


  • Therapeutic Effect of V8 Affecting Mitophagy and Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Mediated by ROS and CHOP Signaling

    by Yong‐Jian Guo, Meng‐Yuan Zhu, Zhan‐Yu Wang, Hong‐Yu Chen, Ying‐Jie Qing, Hong‐Zheng Wang, Jing‐Yan Xu, Hui Hui, Hui Li

    Acute myeloid leukemia (AML) is characterized by the malignant proliferation of abnormally or poorly differentiated myeloid cells in the hematopoietic system. However, there is a lack of effective drugs for treating non‐M3 AML. V8, a newly synthesized derivative of the natural flavonoid wogonin, which is a potential anticancer drug, has demonstrated significant antitumor activity both in vitro and in vivo. Here, we investigated the effects of V8 on AML cell lines and primary AML cells as well as its underlying mechanisms. Our results showed that V8 exerted significant concentration‐dependent growth inhibition and apoptosis induction in AML cells, accompanied by characteristic pathological features including lysosomal functions suppression, mitochondrial dysfunction, and endoplasmic reticulum stress (ERS) activation. Mechanistic investigations revealed that V8 induced mitochondrial membrane potential collapse through elevation of intracellular reactive oxygen species (ROS) levels, while concurrently blocking mitophagy via lysosomal functional inhibition. Furthermore, V8 selectively activated the PERK/p‐eIF2α/ATF4 and IRE1α/XBP1 signaling axes of ERS, ultimately triggering CHOP‐mediated apoptosis through the ERS‐specific pathway. In vivo studies confirmed that V8 treatment significantly prolonged survival duration in NOD/SCID mice bearing primary AML xenografts and suppressed tumor progression in BALB/c nude mice with U937 cell xenografts, with antitumor efficacy closely associated with CHOP‐dependent ERS pathway modulation. These findings not only elucidate the multi‐targeted mechanism of V8 against AML through coordinated regulation of the ROS‐mitochondria‐lysosome‐ERS signaling network, but also provide critical theoretical foundations for developing natural product‐based therapeutics for AML. The multi‐pathway synergistic characteristics exhibited by V8 underscore its considerable potential as a clinically translatable candidate drug.


  • LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1

    by Meng-Yuan Zhu, Ting Wang, Hai-Di Wang, Hong-Zheng Wang, Hong-Yu Chen, Shuai Zhang, Yong-Jian Guo, Hui Li, Hui Hui


  • Open Access

    Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia

    by Yingjie Qing, Xiangyuan Wang, Hongzheng Wang, Po Hu, Hui Li, Xiaoxuan Yu, Mengyuan Zhu, Zhanyu Wang, Yu Zhu, Jingyan Xu, et al.

    Background: The positive transcription elongation factor b (P-TEFb) kinase activity is involved in the process of transcription. Cyclin-dependent kinase 9 (CDK9), a core component of P-TEFb, regulates the process of transcription elongation, which is associated with differentiation and apoptosis in many cancer types. Wogonin, a natural CDK9 inhibitor isolated fromScutellaria baicalensis.This study aimed to investigate the involved molecular mechanisms of wogonin on anti- chronic myeloid leukemia (CML) cells.Materials and methods: mRNA and protein levels were analysed by RT-qPCR and western blot. Flow cytometry was used to assess cell differentiation and apoptosis. Cell transfection, immunofluorescence analysis and co-immunoprecipitation (co-IP) assays were applied to address the potential regulatory mechanism of wogonin. KU-812 cells xenograftNOD/SCIDmice model was used to assess and verify the mechanism in vivo.Results: We reported that the anti-CML effects in K562, KU-812 and primary CML cells induced by wogonin were regulated by P-TEFb complex. We also confirmed the relationship between CDK9 and erythroid differentiation via knockdown the expression of CDK9. For further study the mechanism of erythroid differentiation induced by wogonin, co-IP experiments were used to demonstrate that wogonin increased the binding between GATA-1 and FOG-1 but decreased the binding between GATA-1 and RUNX1, which were depended on P-TEFb. Also, wogonin induced apoptosis and decreased the mRNA and protein levels of MCL-1 in KU-812 cells, which is the downstream of P-TEFb. In vivo studies showed wogonin had good anti-tumor effects in KU-812 xenograftsNOD/ SCIDmice model and decreased the proportion of human CD45+cells in spleens of mice. We also verified that wogonin exhibited anti-CML effects through modulating P-TEFb activity in vivo.Conclusions: Our study indicated a special mechanism involving the regulation of P-TEFb kinase activity in CML cells, providing evidences for further application of wogonin in CML clinical treatment.


  • Open Access

    One‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence

    by Yingjie Qing, Hui Li, Yunzi Zhao, Po Hu, Xiangyuan Wang, Xiaoxuan Yu, Mengyuan Zhu, Hongzheng Wang, Zhanyu Wang, Qinglong Guo, et al.

    T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.


  • Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition

    by Xiaoxuan Yu, Hui Li, Mengyuan Zhu, Po Hu, Xiao Liu, Yingjie Qing, Xiangyuan Wang, Hongzheng Wang, Zhanyu Wang, Jingyan Xu, et al.